0001127602-22-002057.txt : 20220125 0001127602-22-002057.hdr.sgml : 20220125 20220125163732 ACCESSION NUMBER: 0001127602-22-002057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220121 FILED AS OF DATE: 20220125 DATE AS OF CHANGE: 20220125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DeLong Mark Jeffrey CENTRAL INDEX KEY: 0001856078 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 22554355 MAIL ADDRESS: STREET 1: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-01-21 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001856078 DeLong Mark Jeffrey C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Senior Vice President Common Stock 2022-01-21 4 A 0 10592 0 A 20964 D Stock Option (Right to Buy) 35.46 2022-01-21 4 A 0 15024 0 A 2032-01-20 Common Stock 15024 15024 D This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service. This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service. /s/ David Watson, attorney-in-fact for Mark Delong 2022-01-25